These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11771402)

  • 1. Ribozyme-mediated suppression of G protein gamma subunits.
    Robishaw JD; Wang Q; Schwindinger WF
    Methods Enzymol; 2002; 344():435-51. PubMed ID: 11771402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribozymes as tools for suppression of G protein gamma subunits.
    Robishaw JD; Guo ZP; Wang Q
    Methods Mol Biol; 2004; 237():169-80. PubMed ID: 14501049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribozyme-mediated suppression of the G protein gamma7 subunit suggests a role in hormone regulation of adenylylcyclase activity.
    Wang Q; Mullah B; Hansen C; Asundi J; Robishaw JD
    J Biol Chem; 1997 Oct; 272(41):26040-8. PubMed ID: 9325341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
    Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
    Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.
    Bramlage B; Luzi E; Eckstein F
    Nucleic Acids Res; 2000 Nov; 28(21):4059-67. PubMed ID: 11058100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
    Phylactou LA; Tsipouras P; Kilpatrick MW
    Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific gene suppression by engineered ribozymes in monkey cells.
    Cameron FH; Jennings PA
    Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9139-43. PubMed ID: 2556702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient RNA ligation by reverse-joined hairpin ribozymes and engineering of twin ribozymes consisting of conventional and reverse-joined hairpin ribozyme units.
    Ivanov SA; Vauléon S; Müller S
    FEBS J; 2005 Sep; 272(17):4464-74. PubMed ID: 16128815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes.
    Amarzguioui M; Brede G; Babaie E; Grotli M; Sproat B; Prydz H
    Nucleic Acids Res; 2000 Nov; 28(21):4113-24. PubMed ID: 11058107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering a family of synthetic splicing ribozymes.
    Che AJ; Knight TF
    Nucleic Acids Res; 2010 May; 38(8):2748-55. PubMed ID: 20299341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes.
    Byun J; Lan N; Long M; Sullenger BA
    RNA; 2003 Oct; 9(10):1254-63. PubMed ID: 13130139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of new hairpin ribozymes with replaced domains.
    Komatsu Y; Kanzaki I; Koizumi M; Ohtsuka E
    Nucleic Acids Symp Ser; 1995; (34):223-4. PubMed ID: 8841632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection.
    Tang J; Breaker RR
    RNA; 1997 Aug; 3(8):914-25. PubMed ID: 9257650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helicase-attached novel hybrid ribozymes.
    Kawasaki H; Warashina M; Kuwabara T; Taira K
    Methods Mol Biol; 2004; 252():237-43. PubMed ID: 15017053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation and application of asymmetric hammerhead ribozymes.
    Hammann C; Tabler M
    Methods; 1999 Jul; 18(3):273-80. PubMed ID: 10454985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake.
    Bramlage B; Alefelder S; Marschall P; Eckstein F
    Nucleic Acids Res; 1999 Aug; 27(15):3159-67. PubMed ID: 10454613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and anti-HIV-1 activity of ribozymes that cleave HIV-1 LTR.
    Koizumi M; Ozawa Y; Yagi R; Nishigaki T; Kaneko M; Oka S; Kimura S; Iwamoto A; Komatsu Y; Ohtsuka E
    Nucleic Acids Symp Ser; 1995; (34):125-6. PubMed ID: 8841584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of in vivo activities of 5'-connected and 3'-connected cis-acting ribozymes: selection of intracellularly active ribozymes using the gene for dihydrofolate reductase (DHFR) as a selective marker in Escherichia coli.
    Hamada M; Fujita S; Kise H; Jigami Y; Taira K
    J Biochem; 1998 Apr; 123(4):684-92. PubMed ID: 9538262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between tumour necrosis factor alpha ribozyme and cellular proteins. Involvement in ribozyme stability and activity.
    Sioud M
    J Mol Biol; 1994 Oct; 242(5):619-29. PubMed ID: 7932719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.